D.E. Shaw & Co
ENGNW icon

D.E. Shaw & Co’s enGene Therapeutics Warrants ENGNW Stock Holding History

D.E. Shaw & Co’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.3K Hold
104,622
– – ﹤0.01% 4729
2026
Q1 		$275K Hold
104,622
– – ﹤0.01% 4110
2025
Q4 		$314K Hold
104,622
– – ﹤0.01% 4124
2025
Q3 		$75.3K Hold
104,622
– – ﹤0.01% 4380
2025
Q2 		$70.1K Hold
104,622
– – ﹤0.01% 4151
2025
Q1 		$67K Hold
104,622
– – ﹤0.01% 4046
2024
Q4 		$88.9K Hold
104,622
– – ﹤0.01% 4176
2024
Q3 		$209K Hold
104,622
– – ﹤0.01% 4136
2024
Q2 		$145K Hold
104,622
– – ﹤0.01% 4128
2024
Q1 		$544K Sell
104,622
-100
-0.1% -$305 ﹤0.01% 3441
2023
Q4 		$89K Buy
+104,722
New +$80.5K ﹤0.01% 3987

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

D.E. Shaw & Co's ENGNW Position: Q2 2026 in Review

D.E. Shaw & Co held its enGene Therapeutics Warrants (ENGNW) position steady in Q2 2026 at 104,622 shares worth $30.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4729.

D.E. Shaw & Co first reported a position in ENGNW in Q4 2023 and has held it in 11 quarters since. The position peaked at $544K in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

  • D.E. Shaw & Co held 104,622 shares of enGene Therapeutics Warrants worth $30.3K as of Q2 2026.
  • D.E. Shaw & Co left its enGene Therapeutics Warrants share count unchanged in Q2 2026.
  • enGene Therapeutics Warrants made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4729 holding.
  • D.E. Shaw & Co first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 11 quarters since.
  • D.E. Shaw & Co's enGene Therapeutics Warrants position peaked at $544K in Q1 2024.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.